Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Proton pump inhibitors are drugs mainly used for prolong and profound reduction of stomach acid levels in individuals suffering from gastroesophageal reflux disease, hyperacidity and ulcers. Proton pump inhibitors (PPIs) have a unique mechanism of action as they are given in an inactive form which are lipophilic in nature and readily cross cell membranes into intracellular compartments like the parietal cell canaliculus with acidic environments, then the inactive drug is protonated and rearranged into its active form in acidic environments and irreversibly blocks the gastric proton pump of the gastric parietal cells.

The global proton pump inhibitors market is estimated to be valued at US$ 2.9 billion in 2020 and is expected to exhibit a CAGR of 4.30% during the forecast period (2020-2027).

Figure 1. Global Proton Pump Inhibitors Market, by Market value (US$ Bn), by 2016-2027

Proton Pump Inhibitors  | Coherent Market Insights

The increasing prevalence of obesity in adults and adolescents is leading to various conditions related to gastroesophageal reflux disease such as Barret's esophagus (BE), esophageal erosions and esophageal adenocarcinoma. The US National Library of Medicine report published in 2017 stated that individuals with higher body mass index (BMI) have a higher risk of gastrointestinal diseases such as gastroesophageal reflux disease and can lead to esophageal erosions.

Moreover, increasing prevalence of gastrointestinal diseases such as duodenal ulcers, barrets esophagus, and non-erosive reflux disease (NERD) are the factors expected to drive the global proton pump inhibitor market growth. According to US National Library of Medicine report published in July 2020, more than 60% of individuals are suffering from non- erosive reflux disease (NERD) and 30% of people are suffering from barrets esophagus in the US.

request-sample

Proton Pump Inhibitors Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2020: US$ 2.9 Bn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 4.3% 2027 Value Projection: US$ 3.5 Bn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of the Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Type: Omeprazole, Pantaprazole, Rabeprazole, Dexlansoprazole, lansoprazole, Others.
  • By Disease Indication: Ulcers, Gastroesophageal Reflux Disease, Others.
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Others.
Companies covered:

AstraZeneca PLC/AB, Bayer AG, Pfizer Inc., Cadila Pharmaceuticals Limited, Eisai Pharmaceuticals India Pvt. Ltd, Santarus, Inc., Wyeth, LLC, Janssen Pharmaceutica, Takeda Pharmaceutical Company Limited, Sanofi S.A, Aurobindo Pharma, Perrigo Company plc, Dr. Reddy's Laboratories, Aralez Pharmaceuticals Inc., RedHill Biopharma Ltd (ADR) and Cipla Limited

Growth Drivers:
  • The increasing prevalence of gastroesophageal reflux disease and ulcers such as peptic ulcers, duodenal ulcers
  • The increasing presence of local/generic drug manufacturers
  • Strong product pipeline, approval of new proton pump inhibitor drugs for treatment of gastroesophageal reflux disease GERD and ulcers
Restraints & Challenges:
  • Proton pump inhibitors lead to an increase in risk of Clostridium difficile infection of the colon
  • Long term use of PPI may increase risk of osteoporosis-related fractures of the hip, wrist, or spine.

Global Proton Pump Inhibitors Market – Impact of Coronavirus (COVID-19)

Following the outbreak of COVID-19 in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it a public health emergency. According to the World Health Organization’s report, the manifestation of the coronavirus (COVID-19) has resulted in more than 34,804,348 infected individuals worldwide as of 4th October 2020.

COVID-19 can affect tin three main ways; by directly affecting the production and demand; by creating disruptions in distribution channels; and by its financial impact on firms and financial markets. Supply chain and manufacturing activities in India, China, and the U.S. have been disrupted due to nationwide lockdowns. While countries such as Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of drugs from one place to another. Moreover, individuals using proton pump inhibitors medication for longer term duration are more prone towards getting infected by COVID-19 infections.  According to the National Library of Medicine Report published in August 2020, use of proton pump inhibitors can increase risk of COVID-19. Moreover, individuals using proton pump inhibitors twice daily are more likely to get infected by COVID-19. These factors are restraining the growth of global proton pump inhibitor market. Therefore, COVID-19 pandemic has also hampered the global proton pump inhibitor market in negative way.

Figure 2. Global Proton Pump Inhibitors Market share (%), by Region, 2020

Proton Pump Inhibitors  | Coherent Market Insights

Among regions, the North America market is expected to witness significant growth owing to an increasing approvals of proton pump inhibitors products. For instance, in 2017, AstraZeneca plc/AB, a biopharmaceutical and pharmaceutical company, received the U.S. Food Drug and Administration’s approved for use of Nexium (esomeprazole magnesium), for treating gastroesophageal reflux disease in children in the age group of 1 to 11 for short term use.

The Europe proton pump inhibitor market is expected to exhibit significant growth during the forecast period owing to increasing focus of key players on obtaining approvals and on launching products. For instance, in April 2018, Perrigo Company plc and its partner, Dexcel Pharma Technologies, Ltd, announced the launch of novel omeprazole orally disintegrating tablet omeprazole OD, omeprazole OD mouth dissolving tablet approved by the U.S. FDA with MelTech melt-in-your-mouth technology, which dissolves the tablet without water in the mouth. Ompeprazole OD is an over-the-counter medication for treating heartburn.

Key Players

Major players operating in the global proton pump inhibitors market are AstraZeneca PLC/AB, Bayer AG, Pfizer Inc., Cadila Pharmaceuticals Limited, Eisai Pharmaceuticals India Pvt. Ltd, Santarus, Inc., Wyeth, LLC, Janssen Pharmaceutica, Takeda Pharmaceutical Company Limited, Sanofi S.A, Aurobindo Pharma, Perrigo Company plc, Dr. Reddy's Laboratories, Aralez Pharmaceuticals Inc., RedHill Biopharma Ltd (ADR) and Cipla Limited.

The global proton pump inhibitor market includes various drugs which are prescribed by healthcare professionals for treatments related to various gastrointestinal disorders such as duodenal ulcers, peptic ulcers, NSAIDS induced ulcers, and gasteroesophageal reflux disease. Proton pump inhibitors are a class of drugs that act on cell lining of stomach and reduce stomach acid in patients suffering from gastro-intestinal disorders. Proton pump inhibitors include drugs such as esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazol.

Market Dynamics

The global proton pump inhibitor market is expected to witness significant growth during the forecast period owing to focus of generic drug manufactures on obtaining approvals and launching products for treatment of gastro-intestinal diseases to strengthen their position in the global proton inhibitor market. For instance, in March 2020, Rosemont Pharmaceuticals, a pharmaceutical company, launched omeprazole powder for oral suspension, PPI approved for use on mg/kg basis and used in treatment of patients in age groups such as pediatric, adults. The omeprazole powder oral suspension is also licensed for use with percutaneous endoscopic gastonomy (PEG) and nasograstic (NG) tubes.

Key features of the study:

  • This report provides in-depth analysis of the global proton pump inhibitor market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global proton pump inhibitor market based on the following parameters – company overview, financial performance, drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study are AstraZeneca PLC/AB, Bayer AG, Pfizer Inc., Cadila Pharmaceuticals Limited, Eisai Pharmaceuticals India Pvt. Ltd, Santarus, Inc., Wyeth, LLC, Janssen Pharmaceutica, Takeda Pharmaceutical Company Limited, Sanofi S.A., Aurobindo Pharma, Perrigo Company plc, Dr. Reddy's Laboratories
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, market expansion, and marketing tactics
  • The global proton pump inhibitor market report caters to various stakeholders in this industry including investors, suppliers, drugs manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global proton pump inhibitor

Detailed Segmentation:

  • Global Proton Pump Inhibitor Market, By Type:
    • Omeprazole
    • Pantaprazole
    • Rabeprazole
    • Dexlansoprazole
    • lansoprazole
    • Others
  • Global Proton Pump Inhibitor Market, By Disease Indication:
    • Ulcers
    • Gastroesophageal Reflux Disease
    • Others
  • Global Proton Pump Inhibitor Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Others
  • Global Proton Pump Inhibitor Market, By Region:
    • North America
      • By Type:
        • Omeprazole
        • Pantaprazole
        • Rabeprazole
        • Dexlansoprazole
        • lansoprazole
        • Others
      • By Disease Indication:
        • Ulcers
        • Gastroesophageal Reflux Disease
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Others
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Type:
        • Omeprazole
        • Pantaprazole
        • Rabeprazole
        • Dexlansoprazole
        • lansoprazole
        • Others
      • By Disease Indication:
        • Ulcers
        • Gastroesophageal Reflux Disease
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Others
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Type:
        • Omeprazole
        • Pantaprazole
        • Rabeprazole
        • Dexlansoprazole
        • lansoprazole
        • Others
      • By Disease Indication:
        • Ulcers
        • Gastroesophageal Reflux Disease
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Others
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Type:
        • Omeprazole
        • Pantaprazole
        • Rabeprazole
        • Dexlansoprazole
        • lansoprazole
        • Others
      • By Disease Indication:
        • Ulcers
        • Gastroesophageal Reflux Disease
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Others
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Type:
        • Omeprazole
        • Pantaprazole
        • Rabeprazole
        • Dexlansoprazole
        • lansoprazole
        • Others
      • By Disease Indication:
        • Ulcers
        • Gastroesophageal Reflux Disease
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Others
      • By Country/Region:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Type:
        • Omeprazole
        • Pantaprazole
        • Rabeprazole
        • Dexlansoprazole
        • lansoprazole
        • Others
      • By Disease Indication:
        • Ulcers
        • Gastroesophageal Reflux Disease
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Others
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • AstraZeneca PLC/AB *
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Novo Nordisk A/S
    • Bayer AG
    • Pfizer Inc.
    • Cadila Pharmaceuticals Limited
    • Eisai Pharmaceuticals India Pvt. Ltd
    • Santarus, Inc.
    • Wyeth, LLC
    • Janssen Pharmaceutica
    • Takeda Pharmaceutical Company Limited
    • Sanofi S.A.
    • Aurobindo Pharma
    • Perrigo Company plc
    • Dr. Reddy's Laboratories
    • Aralez Pharmaceuticals Inc.
    • RedHill Biopharma Ltd (ADR)
    • Cipla Limited

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Type
      • Market Snippet, By Disease Indication
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
      • Impact Analysis
    • Technological Evolution
    • Regulatory Scenario
    • Key Developments
    • Collaboration and Acquisition
    • Diagnosis Rate/Ratio
    • Pipeline Analysis
    • PEST Analysis
    • Reimbursement Scenario
  4. Global Proton Pump Inhibitors Market, Impact of COVID-19 Pandemic
    • COVID-19 Impact
    • Economic Impact
    • Demand and Supply Impact Analysis
  5. Global Proton Pump Inhibitors Market, By Type, 2016-2027 (US$ Bn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
        • Omeprazole
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Bn)
        • Pantaprazole
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Bn)
        • Rabeprazole
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Bn)
        • Dexlansoprazole
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Bn)
        • Lansoprazole
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Bn)
        • Others
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Bn)
  6. Global Proton Pump Inhibitors Market, By Disease Indication, 2016–2027 (US$ Bn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
        • Ulcers
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Bn)
        • Gastesophageal Reflux Disease
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Bn)
        • Others
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Bn)
  7. Global Proton Pump Inhibitors Market, By Distribution Channel, 2016–2027 (US$ Bn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
        • Segment Trends
          • Hospital Pharmacies
            • Introduction
            • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Bn)
          • Retail Pharmacies
            • Introduction
            • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Bn)
          • Others
            • Introduction
            • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Bn)
  8. Global Proton Pump Inhibitors Market, By Region, 2016–2027 (US$ Bn)
    • Introduction
      • Market Share Analysis, By Country, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Countries, 2017–2027
    • North America
      • Introduction
      • Market Size and Forecast, By Type, 2016–2027 (US$ Bn)
      • Market Size and Forecast, By Disease Indication, 2016–2027 (US$ Bn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Bn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Bn)
        • U.S.
        • Canada
    • Latin America
      • Introduction
      • Market Size and Forecast, By Type, 2016–2027 (US$ Bn)
      • Market Size and Forecast, By Disease Indication, 2016–2027 (US$ Bn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Bn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Bn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Introduction
      • Market Size and Forecast, By Type, 2016–2027 (US$ Bn)
      • Market Size and Forecast, By Disease Indication, 2016–2027 (US$ Bn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Bn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Bn)
        • Germany
        • U.K.
        • France       
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, By Type, 2016–2027 (US$ Bn)
      • Market Size and Forecast, By Disease Indication, 2016–2027 (US$ Bn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Bn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Bn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Introduction
      • Market Size and Forecast, By Type, 2016–2027 (US$ Bn)
      • Market Size and Forecast, By Disease Indication, 2016–2027 (US$ Bn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Bn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Bn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, By Type, 2016–2027 (US$ Bn)
      • Market Size and Forecast, By Disease Indication, 2016–2027 (US$ Bn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Bn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Bn)
        • South Africa
        • Central Africa
        • North Africa
  9. Competitive Landscape
    • Company Profiles
      • AstraZeneca PLC/AB
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Bayer AG
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Pfizer Inc
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Cadila Pharmaceuticals Limited
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Eisai Pharmaceuticals India Pvt. Ltd
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Santarus, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Wyeth, LLC
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Janssen Pharmaceutica
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Takeda Pharmaceutical Company Limited
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Sanofi S.A.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Aurobindo Pharma
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Perrigo Company plc
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Dr. Reddy's Laboratories
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Aralez Pharmaceuticals Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • RedHill Biopharma Ltd (ADR)
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Cipla Limited
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies

*Browse 33 market data tables and 32 figures on "Proton Pump Inhibitor Market – global forecast to 2027”.

Frequently Asked Questions

The global proton pump inhibitor market size is estimated to be valued at US$ 2.9 billion in 2020 and is expected to exhibit a CAGR of 4.30 % between 2020 and 2027.
The increasing prevalence of gastro-intestinal diseases such as duodenal ulcers, gastroesophageal reflux diseases, rising prevalence of obesity in adults which influences GI diseases, strong product pipeline, approval of new proton pump inhibitor drugs for treatment of gastroesophageal reflux disease GERD and ulcers are driving growth of the global proton pump inhibitors market.
Gastroesophageal reflux disease GERD segment is estimated to hold major market share in 2020, owing to the increasing prevalence of gastroesophageal reflux disease in children and adults.
North America is estimated to generate the highest revenue share in 2020 in the global proton pump inhibitors market during the forecast period.
Long term use of proton pump inhibitors leads to toxic epidermal necrolysis and also leads to reduction in kidney functions, prolonged use also reduces absorption of vitamin B12 (cyanocobalamin) is a key factor hampering growth of the market.
Major players operating in the global proton pump inhibitors market are AstraZeneca PLC/AB, Bayer AG, Pfizer Inc., Cadila Pharmaceuticals Limited, Eisai Pharmaceuticals India Pvt. Ltd, Santarus, Inc., Wyeth, LLC, Janssen Pharmaceutica, Takeda Pharmaceutical Company Limited, Sanofi S.A, Aurobindo Pharma, Perrigo Company plc, Dr. Reddy's Laboratories, Aralez Pharmaceuticals Inc., RedHill Biopharma Ltd (ADR) and Cipla Limited.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner